Leading Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEADING
LEADING has seventeen approved drugs.
Summary for Leading
| US Patents: | 0 |
| Tradenames: | 17 |
| Ingredients: | 17 |
| NDAs: | 17 |
Drugs and US Patents for Leading
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leading | CARBINOXAMINE MALEATE | carbinoxamine maleate | TABLET;ORAL | 215476-001 | Dec 19, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | OXYBUTYNIN CHLORIDE | oxybutynin chloride | TABLET;ORAL | 212798-001 | Apr 6, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | PROCHLORPERAZINE MALEATE | prochlorperazine maleate | TABLET;ORAL | 218912-002 | Sep 30, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Leading | BENZTROPINE MESYLATE | benztropine mesylate | TABLET;ORAL | 090168-002 | Nov 28, 2012 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
